IRVINE, Calif. (AP) – Allergan Inc. said May 4 it will license a potential eye-disorder drug from Molecular Partners AG in a deal that could be worth more than $420 million.

The companies said the drug candidate, which is called MP0112, is being studied as a treatment for the retinal diseases diabetic macular edema and “wet” age-related macular degeneration. Both disorders are common causes of impaired vision and

blindness. Allergan said it will pay Molecular Partners $45 million upfront in the deal. It could make up to $375 million in additional payments based on developmental, regulatory and sales milestones.

Molecular Partners will also receive double-digit royalties on sales if the drug is approved. The Swiss company is licensing MP0112 to Allergan only for eye uses.

Allergan also reported its first-quarter results on Wednesday. Its adjusted profit and revenue both surpassed Wall Street estimates, and the company raised its guidance for the full year.

The Associated Press